Literature DB >> 9836764

Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors.

P Trouillas1, N Nighoghossian, L Derex, P Adeleine, J Honnorat, P Neuschwander, G Riche, J C Getenet, W Li, J C Froment, F Turjman, D Malicier, G Fournier, A L Gabry, X Ledoux, Y Berthezène, P Ffrench, M Dechavanne.   

Abstract

BACKGROUND AND
PURPOSE: Although new, large, double-blind, randomized studies are needed to establish the efficiency of intravenous thrombolysis, open trials of sufficient size may also provide novel data concerning specific outcomes after thrombolysis.
METHODS: An open study of intravenous rtPA in 100 patients with internal carotid artery (ICA) territory strokes between 20 and 81 years of age, with a baseline Scandinavian Stroke Scale (SSS) score of <48 at entry was conducted. Inclusion time was within 7 hours after stroke onset. rtPA (0.8 mg/kg) was infused for 90 minutes, with an initial 10% bolus. Heparin was given according to 3 consecutive protocols. The SSS evaluation was done on days 0, 1, 7, 30, and 90. CT scan was performed before treatment, on days 1 and 7. Etiological investigations included echocardiography and carotid Doppler sonography and/or angiography. Outcome at 1 year was documented by SSS score, the modified Rankin Scale (mRS) score, and a 10-point invalidity scale. Multivariate logistic regression was used to identify predictors of poor versus good outcome.
RESULTS: At day 90, 45 patients (45%) had a good result, defined as complete regression or slight neurological sequelae (mRS score of 0-1), 18 patients had a moderate outcome (mRS 2-3), and 31 patients had serious neurological sequelae (mRS 4-5). Six patients died, 2 with intracerebral hematoma after immediate heparin. Five of 11 patients (45.5%) treated between 6 and 7 hours had a good result. The overall intracerebral hematoma rate was 7%. Higher values of fibrin degradation products at 2 hours were observed in the subgroup with intracerebral hematomas. Significant predictors of poor outcome on multivariate logistic regression analysis were baseline SSS score of <15 (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.07 to 10. 74; P=0.04), indistinction between white and gray matter on CT scan (OR, 6.59; 95% CI, 2.19 to 19.79; P=0.0008), and proximal internal carotid thrombosis (OR, 3.29; 95% CI, 0.99 to 10.95; P=0.05).
CONCLUSIONS: Our study confirms the safety of intravenous rtPA at a dose of 0.8 mg/kg and suggests efficacy for this drug even within 7 hours. Outcome and hematoma rates were at least as favorable as for trials of therapy with a 3-hour time window. Subgroups with a poor prognosis include low baseline neurological score, baseline CT changes, and proximal ICA thrombosis. However, approximately 30% of patients with each of these characteristics show a good outcome, so their inclusion in future routine rtPA protocols is still justified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836764     DOI: 10.1161/01.str.29.12.2529

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  24 in total

1.  Intraarterial Thrombolysis with r-tPA for Treatment of Anterior Circulation Acute Ischemic Stroke. Technical and Clinical Results.

Authors:  F Baltacioğlu; N Afşar; G Ekinci; N Tuncer-Elmaci; N Cagatay Cimşit; S Aktan; C Erzen
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

2.  Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Maarten G Lansberg; Martin J O'Donnell; Pooja Khatri; Eddy S Lang; Mai N Nguyen-Huynh; Neil E Schwartz; Frank A Sonnenberg; Sam Schulman; Per Olav Vandvik; Frederick A Spencer; Pablo Alonso-Coello; Gordon H Guyatt; Elie A Akl
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Thrombolysis in acute ischaemic stroke: a guide to patient selection.

Authors:  Richard I Lindley
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice.

Authors:  Dawn M Bravata
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  How to make better use of thrombolytic therapy in acute ischemic stroke.

Authors:  Geoffrey A Donnan; Stephen M Davis; Mark W Parsons; Henry Ma; Helen M Dewey; David W Howells
Journal:  Nat Rev Neurol       Date:  2011-06-14       Impact factor: 42.937

6.  Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics.

Authors:  P N Sylaja; Wei Dong; James C Grotta; Mary K Miller; Kristen Tomita; Scott Hamilton; Charles Semba; Michael D Hill
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

7.  Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation.

Authors:  J M Wardlaw; T M West; P A G Sandercock; S C Lewis; O Mielke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

Review 8.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis.

Authors:  M Arnold; K Nedeltchev; G Schroth; R W Baumgartner; L Remonda; T J Loher; F Stepper; M Sturzenegger; B Schuknecht; H P Mattle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

10.  CT angiography in an acute stroke protocol: correlation between occlusion site and outcome of intravenous thrombolysis.

Authors:  S Porelli; M Leonardi; A Stafa; C Barbara; G Procaccianti; L Simonetti
Journal:  Interv Neuroradiol       Date:  2013-03-04       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.